HC Wainwright Analysts Lift Earnings Estimates for KYTX

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share estimates for Kyverna Therapeutics in a research report issued on Monday, March 30th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.62) per share for the quarter, up from their prior estimate of ($0.88). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.61) EPS.

Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company raised their price objective on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday. Finally, Morgan Stanley set a $33.00 price target on shares of Kyverna Therapeutics in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.67.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $8.63 on Wednesday. The company has a 50-day moving average price of $8.26 and a 200-day moving average price of $7.69. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $13.67. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $377.99 million, a P/E ratio of -2.36 and a beta of 3.32.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Thursday, March 26th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.80).

Institutional Trading of Kyverna Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYTX. Empowered Funds LLC bought a new position in shares of Kyverna Therapeutics in the 4th quarter worth $169,000. Quadrature Capital Ltd purchased a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $539,000. Millennium Management LLC lifted its stake in Kyverna Therapeutics by 7.6% during the 4th quarter. Millennium Management LLC now owns 593,369 shares of the company’s stock valued at $5,578,000 after acquiring an additional 41,734 shares during the period. Balyasny Asset Management L.P. acquired a new position in Kyverna Therapeutics during the fourth quarter valued at $9,220,000. Finally, 683 Capital Management LLC acquired a new position in shares of Kyverna Therapeutics in the 4th quarter valued at about $1,080,000. Institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.